BCAB Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

BioAtla Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerBCAB

Market Cap6.4M

Cash RunwayRunway < 6 months

Next Catalyst2028-09-15

Public Research Snapshot

BioAtla Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for CAB-AXL-ADC in Non-Small-Cell Lung Cancer (Phase 2) using Adc.

Pipeline

Asset	Indication	Modality	Stage	Public Note
Features	n/a	n/a	n/a	Public pipeline row
Benefits	n/a	Antibody	n/a	Public pipeline row
Strong IP Protection	n/a	Adc	n/a	Public pipeline row
Comprehensive Integrated Antibody Optimization	n/a	Antibody	n/a	Public pipeline row
CAB-ROR2-ADC	Non Small Cell Lung Cancer \| Triple Negative Breast Cancer \| Melanoma \| Head and Neck Cancer	Adc	Phase 1 \| Phase 2	Public pipeline row
CAB-AXL-ADC	Non-Small-Cell Lung Cancer	Adc	Phase 2	Public pipeline row
BA3182	Advanced Adenocarcinoma	Bispecific	Phase 1	Public pipeline row
Durvalumab	Ovarian Cancer	n/a	Phase 2	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2028-09-15	BA3182	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT03504488	Phase 1 \| Phase 2	COMPLETED	132	2024-12-30
NCT04681131	Phase 2	COMPLETED	85	2025-07-09
NCT05271604	Phase 2	COMPLETED	42	2025-09-22
NCT04918186	Phase 2	RECRUITING	60	2026-06-30
NCT05808634	Phase 1	RECRUITING	168	2028-09-15

Scientific Context

literature_publication | Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.
literature_publication | Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial.
literature_publication | Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugate.
literature_publication | Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study.
literature_publication | Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody-drug conjugate.

Want the full BCAB research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.